Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Daiichi Sankyo Ltd ADR (OP:DSNKY)

21.94 -0.20 (-0.90%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Daiichi Sankyo Ltd ADR

< Previous 1 2 3 Next >
AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu... 
Via Benzinga
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3... 
Via Benzinga
Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu
Daiichi Sankyo Co Ltd (OTC: DSKYF) and AstraZeneca plc (NASDAQ: AZN) have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (... 
Via Benzinga
Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan
Daiichi Sankyo Co Ltd (OTC: DSNKY) said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason. However, the... 
Via Benzinga
Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters
Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro... 
Via Benzinga
AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program... 
Via Benzinga
LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates
CANbridge Pharmaceuticals Inc has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics Inc (NASDAQ: LOGC) to... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.